Investor Jordi Visser cites Lilly’s AI-driven drug discovery and proprietary metabolic data as catalysts for potential $1.08 trillion valuation.
Eli Lilly could surpass Nvidia and become the world’s largest company within five years, driven by its AI infrastructure and proprietary metabolic disease data, according to investor Jordi Visser. The pharmaceutical firm’s decades-long data trove creates a competitive moat unmatched by public AI models, positioning it for significant valuation growth.
Lilly’s GLP-1 drugs for obesity and diabetes have already fueled market momentum, but its AI-powered drug discovery platform remains underappreciated by investors. Current valuations treat it as a traditional pharma stock, overlooking its potential as an AI-driven innovation leader.
Visser argues that Lilly’s unique data advantage, combined with blockbuster treatments, could unlock a rerating of its market capitalization, rivaling tech giants like Nvidia.